The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting regulatory progress within the biotechnology sector, Galectin Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) supporting the advancement of its drug belapectin. According to reports, this support was received during a Type C meeting held to discuss the clinical path forward for the treatment of MASH cirrhosis and portal hypertension. The meeting focused on defining the developmental trajectory for patients suffering from advanced liver disease.
Sign in to access this content
Sign InThis regulatory milestone occurs amidst intensifying competition in the MASH treatment market, following Madrigal Pharmaceuticals' landmark FDA approval for Rezdiffra earlier in 2024, which has heightened investor interest in the sector. Per market data, clinical-stage biotech firms are seeing increased volatility as regulatory clarity becomes a primary driver for valuation shifts in the liver disease therapeutic space.
GALT shares closed at $2.83 (close June 18, 2026), having reached an intraday high of $2.93. Investors should monitor upcoming clinical trial timelines as key catalysts, particularly following the Fed's decision to hold interest rates at 3.75% on June 17, 2026, which maintains a consistent cost-of-capital environment for research-heavy biotech entities.